Co-Authors
This is a "connection" page, showing publications co-authored by Jeffrey Kordower and Roy Bakay.
Connection Strength
0.631
-
Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 2014 Jul; 29(8):999-1009.
Score: 0.113
-
Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.
Score: 0.087
-
Postmortem study of deep brain stimulation of the anterior thalamus: case report. Neurosurgery. 2008 Feb; 62(2):E530-2; discussion E532.
Score: 0.076
-
Deep brain stimulation for treatment of obesity in rats. J Neurosurg. 2007 Oct; 107(4):809-13.
Score: 0.074
-
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis. 2007 Apr; 26(1):56-65.
Score: 0.071
-
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006 Dec; 60(6):706-15.
Score: 0.070
-
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002 Jun 15; 22(12):4942-54.
Score: 0.052
-
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81.
Score: 0.029
-
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
Score: 0.023
-
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther. 2008 Oct; 16(10):1737-44.
Score: 0.020
-
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005 May; 11(5):551-5.
Score: 0.016